From June 22nd to 23rd, the APM 2021 Asia Pharmaceutical Industry Conference, hosted by SRI Consulting and supported by the China Chemical Pharmaceutical Industry Association, Shanghai Pharmaceutical Industry Association, and International Pharmaceutical Engineering Association, with CPharm as a strategic cooperation unit, was successfully held at the Renaissance Shanghai Hotel in Hongqiao, Shanghai. As an expert in the biopharmaceutical field, Mr. Mao Hua, Partner and Managing Director of Frost & Sullivan's Greater China region, was invited to attend this sub-forum event and deliver a keynote speech. He analyzed the current situation of China's biopharmaceutical industry and looked ahead to its future development.
Zhao Hui, Deputy Secretary-General of the Shanghai Pharmaceutical Industry Association, presides over the conference
Opening Remarks by Pan Guangcheng, Executive President of the Chinese Chemical Pharmaceutical Industry Association
Opening Remarks by Zhang Ping, President of the International Pharmaceutical Engineering Association China Region and Head of the Industrial Affairs Department for China at Sanofi
At the Biopharmaceutical Sub-forum, Mr. Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, delivered a keynote speech titled 'Analysis of the Transformation of China's Pharmaceutical Industry and Future Market Development'.
He pointed out that China is currently in an era of first-mover imitation and rapid follow-up by international innovative drugs, with the core competitiveness of the pharmaceutical industry undergoing a transformation from marketing to research and development innovation. Affected by the COVID-19 pandemic, the Chinese chemical drug market declined in 2020, while biopharmaceuticals continued to grow at a high rate. Currently, the market is mainly dominated by monoclonal antibody drugs, and in the future, more innovative types will expand the biopharmaceutical market together.
He said: 'In the next five years, with the development of China's innovative drug market, innovative biopharmaceuticals, including antibodies, gene and cell therapies, will be a hot topic in the development of China's pharmaceutical market.'
At the meeting, 47 expert representatives from the pharmaceutical industry, including Fosun Pharma, Shanghai Pharmaceutical, Yangtze River Pharmaceutical, Hengrui Medicine, Luye Pharma, Qilu Pharma, Shandong Xinhua Pharmaceutical, North China Pharmaceutical, Wuhan Tianjin Pharmaceutical, Chuangxiang Biotech, Yasheng Medicine, Fuxing Kait, and Zai Ding Medicine, discussed in depth under the theme of "Nourishing Life, Innovating for a New Journey, and Winning Together for the Future," the new trends, changes, and demands in the development of the pharmaceutical industry under healthcare reform, with the aim of jointly promoting the healthy and high-quality development of the pharmaceutical industry.
